Bisphosphonates and osteoprotegerin as inhibitors of myeloma bone disease
نویسندگان
چکیده
منابع مشابه
RANK ligand and osteoprotegerin in myeloma bone disease.
Myeloma bone disease is due to interactions of myeloma cells with the bone marrow microenvironment, and is associated with pathologic fractures, neurologic symptoms and hypercalcemia. Adjacent to myeloma cells, the formation and activation of osteoclasts is increased, which results in enhanced bone resorption. The recent characterization of the essential cytokine of osteoclast cell biology, rec...
متن کاملAn osteoprotegerin-like peptidomimetic inhibits osteoclastic bone resorption and osteolytic bone disease in myeloma.
Multiple myeloma is a B-cell malignancy characterized by the uncontrolled growth of plasma cells in the bone marrow and the development of osteolytic bone disease. Myeloma cells express the receptor activator of nuclear factor kappaB ligand (RANKL), induce RANKL expression in the bone marrow, and down-regulate expression of the decoy receptor osteoprotegerin, thereby promoting bone resorption. ...
متن کاملBisphosphonates and metastatic bone disease.
Malignant bone disease is a frequent complication of several common solid tumours including breast, lung, prostate and renal cancer. A greater understanding of tropic bone tumour cells, especially the understanding of those properties which lead to their successful growth within the bone microenvironment is the first step to devise innovative approaches. Bone metastases are generally characteri...
متن کاملNovel bisphosphonates as inhibitors of isoprenoid biosynthesis
Statins and nitrogenous bisphosphonates (NBPs) are clinically used inhibitors of the mevalonate pathway, which is the pathway responsible for cholesterol production as well as other isoprenoid-derived molecules. Through the inhibition of HMGCR and FDPS, respectively, these drugs deplete cells of FPP and can disrupt downstream cellular processes such as protein prenylation. At the major branch p...
متن کاملMULTIPLE MYELOMA Myeloma bone disease
Bone destruction is a hallmark of multiple myeloma, and recent studies demonstrated a strong interdependence between tumor progression and bone resorption. Increased bone resorption as a major characteristic of multiple myeloma is caused by osteoclast activation and osteoblast inhibition (uncoupling). Myeloma cells alter the local regulation of bone metabolism by increasing the receptor activat...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Cancer
سال: 2003
ISSN: 0008-543X,1097-0142
DOI: 10.1002/cncr.11125